MSB 3.21% $1.13 mesoblast limited

Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD, page-216

  1. 1,937 Posts.
    lightbulb Created with Sketch. 498
    Hi Granger,

    Your comments regarding it being risky to not do a trial is a little ambiguous. You started the paragraph with what SI said - did he also echo the above sentiment - risk in not completing a trial - or was that your add on?

    Thanks.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.